A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil

Key facts

Sponsor

Pontificia Universidade Católica do Rio Grande do Sul

Principal Investigator

Douglas K Sato

Pontifical Catholic University of Rio Grande do Sul

Intervention

anti-aquaporin-4 antibody(diagnostic_test)

Enrollment

100 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2025

Study locations (8)

• Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil
• Instituto de Neurologia de Curitiba, Curitiba, Paraná, Brazil
• Hospital da Restauração de Recife, Recife, Pernambuco, Brazil
• Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
• Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
• Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
• Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto / Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
• Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil

Collaborators

Teva Pharmaceuticals USA

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Pediatric multiple sclerosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07571304
  Dual-Task Training in Pediatric Multiple Sclerosis
  Istanbul University - Cerrahpasa
• ACTIVE NOT RECRUITINGNCT04593082
  Obesity and Pediatric Multiple Sclerosis
  University of Virginia
• ACTIVE NOT RECRUITINGNANCT04782466
  ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program
  The Hospital for Sick Children
• ACTIVE NOT RECRUITINGPHASE3NCT01892722
  Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
  Novartis Pharmaceuticals

See all trials for Pediatric multiple sclerosis →